Rapid Dose Therapeutics to Pay High-Interest Note Obligations in Shares

Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Rapid Dose Therapeutics Corp ( (TSE:DOSE) ) has shared an announcement. Rapid Dose Therapeutics Corp. has announced it will pay the March 31, 2026 quarterly interest on its amended and restated secured convertible notes by issuing common shares instead of cash. The notes, originally created through a 2023 private placement financing of over $3.1 million and later extended to November 30, 2026 with 18% annual interest payable in shares, will result in the issuance of 1,263,001 shares at $0.11 each to satisfy approximately $138,932 of accrued interest, with the new shares subject to a four-month hold period. The move underscores the company’s continued reliance on equity-based financing to service high-interest debt arising from its prior capital raise, which may help preserve cash for operations while modestly diluting existing shareholders. By extending both the maturity of the notes and the expiry of associated warrants, RDT is effectively managing its near-term liquidity obligations while keeping investors engaged through convertible and warrant-linked upside tied to its drug delivery technology business. The most recent analyst rating on (TSE:DOSE) stock is a Hold with a C$0.09 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page. Spark’s Take on DOSE Stock According to Spark, TipRanks’ AI Analyst, DOSE is a Neutral. The score is mainly held down by weak financial performance—large ongoing losses, negative equity, and continued cash burn—indicating elevated funding and execution risk. Technicals also reflect a clear downtrend despite oversold conditions. Valuation provides limited support due to negative earnings and no indicated dividend yield. To see Spark’s full report on DOSE stock, click here. More about Rapid Dose Therapeutics Corp Rapid Dose Therapeutics Corp. is a Canadian biotechnology company focused on innovative drug delivery systems. Its flagship product, QuickStrip, is a thin, orally dissolvable film that can deliver nutraceuticals, pharmaceuticals and vaccines rapidly into the bloodstream, targeting markets that require fast onset and convenient administration of active ingredients. Average Trading Volume: 139,012 Technical Sentiment Signal: Sell Current Market Cap: C$15.83M See more data about DOSE stock on TipRanks’ Stock Analysis page.